Canada · Delayed Price · Currency is CAD Cannara Biotech Statistics
Total Valuation
Cannara Biotech has a market cap or net worth of CAD 173.72 million. The enterprise value is 206.79 million.
| Market Cap | 173.72M |
| Enterprise Value | 206.79M |
Important Dates
The last earnings date was Friday, July 18, 2025.
| Earnings Date | Jul 18, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Cannara Biotech has 91.43 million shares outstanding. The number of shares has increased by 0.64% in one year.
| Current Share Class | 91.43M |
| Shares Outstanding | 91.43M |
| Shares Change (YoY) | +0.64% |
| Shares Change (QoQ) | +0.38% |
| Owned by Insiders (%) | 2.34% |
| Owned by Institutions (%) | 0.24% |
| Float | 44.71M |
Valuation Ratios
The trailing PE ratio is 11.19 and the forward PE ratio is 19.00.
| PE Ratio | 11.19 |
| Forward PE | 19.00 |
| PS Ratio | 1.71 |
| PB Ratio | 1.76 |
| P/TBV Ratio | 1.76 |
| P/FCF Ratio | 11.59 |
| P/OCF Ratio | 8.53 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.50, with an EV/FCF ratio of 13.80.
| EV / Earnings | 13.33 |
| EV / Sales | 2.03 |
| EV / EBITDA | 7.50 |
| EV / EBIT | 9.68 |
| EV / FCF | 13.80 |
Financial Position
The company has a current ratio of 2.43, with a Debt / Equity ratio of 0.48.
| Current Ratio | 2.43 |
| Quick Ratio | 0.82 |
| Debt / Equity | 0.48 |
| Debt / EBITDA | 1.72 |
| Debt / FCF | 3.17 |
| Interest Coverage | 5.19 |
Financial Efficiency
Return on equity (ROE) is 17.21% and return on invested capital (ROIC) is 9.65%.
| Return on Equity (ROE) | 17.21% |
| Return on Assets (ROA) | 8.37% |
| Return on Invested Capital (ROIC) | 9.65% |
| Return on Capital Employed (ROCE) | 15.77% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.64 |
| Inventory Turnover | 1.31 |
Taxes
In the past 12 months, Cannara Biotech has paid 1.84 million in taxes.
| Income Tax | 1.84M |
| Effective Tax Rate | 10.59% |
Stock Price Statistics
The stock price has increased by +206.45% in the last 52 weeks. The beta is 0.26, so Cannara Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.26 |
| 52-Week Price Change | +206.45% |
| 50-Day Moving Average | 1.54 |
| 200-Day Moving Average | 1.17 |
| Relative Strength Index (RSI) | 61.88 |
| Average Volume (20 Days) | 117,912 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Cannara Biotech had revenue of CAD 101.87 million and earned 15.52 million in profits. Earnings per share was 0.17.
| Revenue | 101.87M |
| Gross Profit | 45.31M |
| Operating Income | 21.36M |
| Pretax Income | 17.36M |
| Net Income | 15.52M |
| EBITDA | 27.30M |
| EBIT | 21.36M |
| Earnings Per Share (EPS) | 0.17 |
Balance Sheet
The company has 14.41 million in cash and 47.47 million in debt, giving a net cash position of -33.06 million or -0.36 per share.
| Cash & Cash Equivalents | 14.41M |
| Total Debt | 47.47M |
| Net Cash | -33.06M |
| Net Cash Per Share | -0.36 |
| Equity (Book Value) | 98.59M |
| Book Value Per Share | 1.08 |
| Working Capital | 49.39M |
Cash Flow
In the last 12 months, operating cash flow was 20.37 million and capital expenditures -5.39 million, giving a free cash flow of 14.99 million.
| Operating Cash Flow | 20.37M |
| Capital Expenditures | -5.39M |
| Free Cash Flow | 14.99M |
| FCF Per Share | 0.16 |
Margins
Gross margin is 44.48%, with operating and profit margins of 20.97% and 15.23%.
| Gross Margin | 44.48% |
| Operating Margin | 20.97% |
| Pretax Margin | 17.04% |
| Profit Margin | 15.23% |
| EBITDA Margin | 26.80% |
| EBIT Margin | 20.97% |
| FCF Margin | 14.71% |
Dividends & Yields
Cannara Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.64% |
| Shareholder Yield | n/a |
| Earnings Yield | 8.93% |
| FCF Yield | 8.63% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on February 13, 2023. It was a reverse split with a ratio of 0.1.
| Last Split Date | Feb 13, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
Cannara Biotech has an Altman Z-Score of 2.03 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.03 |
| Piotroski F-Score | 8 |